HCV NS5a Subtype; Daclatasvir Resistance; Ledipasvir Resistance; Ombitasvir Resistance
For detection of mutations in the NS5a gene associated with resistance to NS5a inhibitors (examples: daclatasvir, ledipasvir, ombitasvir, elbasvir and velpatasvir). Testing for NS5a resistance-associated variants prior to initiation of treatment with elbasvir plus grazoprevir in HCV genotype 1a infected patients is recommended.
2.0 mL Plasma from a Lavender Top Tube - EDTA in a Plastic Vial
72 hours Ambient
14 days Refrigerated (transport)
42 days Frozen
Separate plasma from whole blood within 24 hours of collection by centrifugation. Transfer to a plastic screw-cap vial and refrigerate or freeze.
0.6 mL Plasma
Not Detected
For detection of mutations in the NS5a gene associated with resistance to NS5a inhibitors (examples: daclatasvir, ledipasvir, ombitasvir, elbasvir and velpatasvir). Testing for NS5a resistance-associated variants prior to initiation of treatment with elbasvir plus grazoprevir in HCV genotype 1a infected patients is recommended.
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
2 to 4 days
00913956
87902